To include your compound in the COVID-19 Resource Center, submit it here.

Oxygent perflubron: Phase III

ALLP said preliminary analyses of Phase III safety data showed no evidence linking Oxygent to adverse events, primarily

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE